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Patient is a 61 year old P3 postmenopausal female who presented to
the ED with a left labial mass and vulvar pain, worsening over the past
2 months. Patient's past gynecologic history is signiﬁcant for chronic
vulvar hidradenitis suppurativa (Hurley Stage III) and obesity (BMI
31). Other comorbidities included well controlled hypertension.
On Image 1, the initial external pelvic exam is shown. The patient's1. Introduction
Hidradenitis suppurativa (HS) is a chronic and recurrent inﬂamma-
tory follicular occlusive disease involving the follicular portion of
folliculopilosebaceous units (FPSUs) of the skin (Jemec and Hansen,
1996). The pathophysiology of the disease involves follicular occlusion,
follicular rupture, with an associated immune response that leads to the
formation of abscesses, sinus tracts, scarring, and ultimately severe
diffuse involvement (Pena et al., 2015). Associated factors include
obesity, smoking, genetic susceptibility, and mechanical stresses on
the skin. Most commonly affected areas of the body are those bearing
apocrine-glands, such as the axilla, inguinal area, and anogenital
regions. In females, it usually targets the gluteal and pudendal areas
and is characterized by painful nodules, abscesses, ﬁstulas, sinus tracts,
comedones and scarring, which may lead to severe functional and
psychological impairment (Alikhan et al., 2009).
It has been theorized that these chronic insults to skin can lead to
proliferative epidermal changes as well as malignancy (Donsky and
Mendelson, 1964; Anstey et al., 1990). Squamous cell carcinoma arising
in hidradenitis suppurativa/acne inversa (HS/AI) is rare and more
commonly found in men (Maclean and Coleman, 2007; Mendonça
et al., 1991). A review of all published cases of SCC showed that 48% of
these patients died within 2 years of SCC recognition (Maclean and
Coleman, 2007). To our best knowledge, it has been reported in at
least 64 cases (Alikhan et al., 2009).
We report a case of a womanwho developed squamous cell carcino-
ma of the vulva in the setting of chronic, long-standing hidradenitis
suppurativa.ta).
. This is an open access article underexternal genitalia showed areas affected by severe, chronic hidradenitis
suppurativa with marked hyperkeratosis with darkened areas of
ﬁbrosis. Most signiﬁcantly, her left labia majora contained a large,
friable 10 × 7 cm mass with white scaling and verrucous appearance.
Patient underwent a vulvar biopsy which revealed a focus of a well-
differentiated, keratinizing squamous cell carcinoma. MRI of the pelvis
revealed diffuse, nodular skin thickening along the pelvic folds, up to
2.3 cm in depth with subcentimeter, rim-enhancing nodules that may
represent abscesses with no ﬁstula or intrapelvic extension. Additional-
ly, the patient had a 3.1 cm diffusely thickened endometrial stripe and a
ﬁbroid uterus. The ﬁndings were noted to be compatible with chronic
hidradenitis. Patient had a subsequent PET scan which was negative
for distant metastasis.
Patient underwent a radical hemivulvectomy, bilateral groin nodal
dissection and endometrial curettings which left a large defect in the
perineummeasuring 12 × 6 cm (Image 2). Reconstruction of perineum
was performed using perforator ﬂap followed by two vascularized
fasciocutaneous ﬂap closures of thigh donor site. At the completion of
the procedure, 4 Jackson-Pratt drains were placed (2 in bilateral ingui-
nal node dissection and 2 in reconstructive ﬂap).
In this obese patient undergoing vulvar reconstruction with
superimposed hidradenitis suppurativa, the postoperative course was
further complicated by surgical site infection requiring multiple
debridement procedures and prolonged courses of IV antibiotics
(Vancomycin, Piperacillin, Tazobactam, Ceftrizone, Flagyl) with twice
daily dressing changes with Dakins solution (Image 3). After 2 weeks
of therapy the surgical site was minimally healed with persistent swell-
ing, deep ﬁssures and purulent drainage noted. The patient was started
on high dose steroid therapy (IV solumedrol 100 mg IV daily as well as
one time injection of triamcinolone 60 mg), Vitamin C 1 g PO daily
and Zinc Sulfate 220 mg PO. This regimen resulted in signiﬁcant
improvement in healing of the surgical wound. In addition, inﬂiximab
therapy was considered however the patient declined due to potential
associated side effects.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Image 1. Initial external pelvic examination.
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gynecologic oncology team. The most recent images taken 8 months
after surgery demonstrate a well healed vulva (Image 4). The ﬁnal
pathology revealed a mass with a well to differentiated, keratinizing
squamous cell carcinoma; the tumor penetrated the specimen to 60%
of its thickness (15 mm/25 mm). No deﬁnite lymphovascular space
invasion was identiﬁed. All margins were free of tumor with the closestImage 2. Status post radical hemivulvectomy creating a large defect that required
intervention by plastic surgery.approaching the medial margin at 4 mm. The patient did not require
postoperative adjuvant therapy and remains without evidence of
disease.
3. Discussion
Our case highlights a rare consequence of long-standing poorly con-
trolled hidradenitis suppurativa: squamous cell carcinoma. AlthoughImage 3. Status post wound revision secondary to wound separation and infection.
Image 4. Surgical site 8 months after surgery.
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squamous cell carcinoma in the setting of HS/AI is thought to be a rare
occurrence. Lavogiez et al. (2010) quoted an incidence of 4.6% in their
cohort of 217 patients with HS with a stronger preference for males
(4:1 ratio) (Maclean and Coleman, 2007; Mendonça et al., 1991). The
prognosis is poor due to the advanced stage of SCC at time of diagnosis
and difﬁculty in obtaining a biopsy. Frequently there is a delay in
diagnosis of SCC and deﬁnitive surgical management. In a recent review
of published cases of squamous cell carcinoma originating from HS/AI
(Losanoff et al., 2011), the majority of events were described in the
context of long-standing, chronic HS/AI (20–30 years)with 50%mortal-
ity noted from metastatic disease. It is thought that infection with the
human papillomavirus is a risk factor for the development of SCC in
patients with HS/AI.
HS should be treated early to avoid chronic progression of the
disease that could ultimately lead to a rare but fatal consequence of
HS/AI: the development of SCC (Lavogiez et al., 2010). Treatment should
be tailored to the level of disease severity of HS/AI. In early stages,
approaches to treatment include non-pharmacologic methods such as
avoidance of skin trauma, hygiene, smoking cessation and weight
management. Pharmacologic methods include topical clindamycin as
ﬁrst-line therapy, topical resorcinol (a chemical peeling agent),
intralesional corticosteroids or systemic antibiotics. The cases of chronic
and severe HS/AI require a more aggressive approach to avoid the
chronic progression of the disease; in these cases, early surgical treat-
ment in the form of complete excision is oftenwarrantedwhenmedical
therapies fail (Losanoff et al., 2011). Furthermore, a high index of
suspicion and early tissue diagnosis should be performed in those
with suspicion of malignancy. Previous authors have advocated that
HS/AI arising in extra-axillary sites be regarded as a pre-malignant
condition and not treated conservatively. Close follow-up and repeated
skin biopsies should be performed in those with suspected malignancy.
In our patient, further complications after surgery included poor
post-operative wound healing due to underlying HS/AI. Though previ-
ously thought to be related to infected sweat glands, current hypotheses
is that hidradenitis suppurativa/acne inversa results from the “follicular
triad” which includes follicular occlusion, follicular rupture, and an
associated immune response (Danby and Margesson, 2010). Despite
this new hypothesis, the role of the immune system as a contributor
to the initiation of HS/AI has not been previously well studied. In ourpatient, high dose high potency steroid therapy resulted in a signiﬁcantly
decreased inﬂammatory reaction associated with HS. This ultimately led
to better wound healing despite concomitant superimposed infection.
The difﬁculty in treating severe and refractory cases of HS/AI has
prompted researchers to study the effects of biologic agents routinely
used for psoriasis and rheumatoid arthritis (Lee and Eisen, 2015). In
particular, adalimumab and inﬂiximab have been shown to be efﬁca-
cious in treating HS/AI, although further investigation is warranted;
such novel use of biologic therapies to decrease the inﬂammatory
reaction associated with HS/AI is important for the gynecologic oncolo-
gist to consider when treating these complex surgical cases.
In summary, there should be a high index of suspicion for malignan-
cy in patients with chronic, long-standing HS/AI; these patients should
not undergo a delay in diagnosis or delay in deﬁnitive treatment in
the form of surgical resection. In addition, prior to surgical intervention,
every effort should be made to optimize surgical outcomes and wound
healing, including a multi-disciplinary approach including plastic
surgery and dermatology consultation.
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